Bluebird Bio stock is in a strong uptrend as the number of analysts with Buy ratings surge.
BTIG upgraded Bluebird Bio stock from Neutral to Buy, and set a price target of $177. BTIG thinks that positive signals are coming from the FDA concerning bluebird bio's latest CAR-T therapy for advanced stage multiple myeloma patients. Earlier this year, bluebird bio's precursor to bb21217, named bb2121, delivered a 100% response rate among 15 multiple myeloma patients.
Author: Lance Jepsen
For ethical purposes, I try not to hold any position in any stock I profile on GuerillaStockTrading.com unless specifically stated in the article. Owner of GuerillaStockTrading.com. Seasoned entrepreneur, investor, and writer. I love God, family, country, stock trading, economics, and helping people learn how to trade. View all posts by Lance Jepsen